Aims Antiretrovirals (ARVs) have transformed HIV prognosis; most individuals will take
treatment lifelong and will enjoy a normal life expectancy. Based on 2015/6 ARV …

Objectives Reliable and timely HIV care cost estimates are important for policy option
appraisals of HIV treatment and prevention strategies. As HIV clinical management and …

Methods The number of people taking each antiretroviral in the UK was estimated from
23,655 individuals in the UK CHIC cohort (2012 database). Costs of patented drugs were …

Background In the Netherlands, the annual expenditure on HIV care was 202 million euros
in 2019, with about 70% allocated to antiretroviral therapy (ART). The introduction of generic …

Introduction: The use of lifelong antiretroviral therapy (ART) results in increased costs of
care; the ability to finance and control sustained costs of ART needs to be discussed …

Background Treatment guidelines for antiretroviral therapy (ART) have evolved to
emphasize newer regimens that address ageing-related comorbidities. Using national …

Introduction Simulation studies showed that generic antiretroviral (ARV) drug utilization
could lead to significant cost reduction of HIV treatment in developed world. This study …

Objectives The incremental costs of expanding antiretroviral (ARV) drug treatment to all HIV‐
infected patients are substantial, so cost‐saving initiatives are important. Our objectives …

There is interest in introducing generic antiretroviral drugs (ARVs) into high-income
countries in order to maximise efficiency in health care budgets. Studies examining patients' …

Objectives: In this study, we first assessed costs associated with the use of antiretroviral
therapy (ART) in an infectious diseases University Hospital Clinic; second, we evaluated …